Form 4: Revance Therapeutics Director Chris Nolet Receives Stock Awards

Director Chris Nolet of Revance Therapeutics received 15,000 shares of common stock and an option to purchase 23,458 shares on May 1, 2024.

Summary

• Chris Nolet, a director at Revance Therapeutics, received an annual restricted stock award of 15,000 shares on May 1, 2024, at a price of $0 per share.
• These shares will vest on the earlier of May 1, 2025, or the day before the next annual stockholder meeting, contingent upon continuous service as a director.
• Nolet also received a stock option to purchase 23,458 shares of common stock at an exercise price of $3.795 per share.
• This option also vests on the earlier of May 1, 2025, or the day before the next annual stockholder meeting, subject to continuous service.
• Following these transactions, Nolet beneficially owns 43,606 shares of common stock and options for 23,458 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard director compensation practices, aligning director interests with shareholders through equity.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock awards.

Industry Context

Stock awards and options are common forms of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages typically include a mix of cash, stock, and options.
• The specific amounts and vesting schedules vary widely based on company size, industry, and individual contributions.
• Comparing Revance's director compensation to peers like Allergan (now AbbVie) or Evolus would provide a more detailed benchmark.

Stakeholder Impact

• The stock awards align the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• The awards do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Revance Therapeutics, Director Compensation, Stock Options, Restricted Stock Award, RVNC, Chris Nolet, Beneficial Ownership, Form 4